Stemokin in treatment and prevention of pyoderma in military personnel
V. V. Gladko, N. N. Kakhishvili, S. A. Masyukova · 2015 · See linked publication
What does this source report?
The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.
- Population and setting
- Source-specific experimental population
- Evidence type
- Human comparative study
- Preparation
- Defined synthetic peptide / analogue
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Russian conference abstract read. Full dissertation and participant-overlap audit remain pending.
Recorded source-check date: 2026-10-02. This date does not imply a completed systematic review.
Cite and trace this record
Original source: V. V. Gladko, N. N. Kakhishvili, S. A. Masyukova. Stemokin in treatment and prevention of pyoderma in military personnel See linked publication 2015.
Molekul research summary: https://molekul.io/research/gaps-stemokin-2015. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry